Lubrizol, a specialty chemical manufacturer, has announced the results of a clinical study demonstrating that the combination of Argireline® Amplified peptide and botulinum toxin type A (BTA) injections can keep wrinkles at bay for nearly 8 weeks longer than BTA alone. This naturally occurring peptide not only enhances but prolongs the anti-aging effects of cosmetic injections, providing a longer-lasting solution for wrinkle reduction.
An evolution of the world-renowned Argireline® peptide and designed following the principles of Green Chemistry, the Amplified Argireline® peptide features superior in vitro activity and added muscle relaxation effects compared to the original Argireline® peptide. Initially used in topical treatments as a non-invasive alternative to reduce facial muscle activity, Argireline® Amplified peptide has been clinically shown to significantly prolong the effects of BTA injections when used in combination.
In the recent study, 45 Caucasian male and female volunteers between the ages of 35 and 60 received 50 IU of botulinum toxin type A injected into crow's feet, frown lines and forehead areas. They also applied a cream containing 5% Argireline® Amplified peptide solution or a placebo cream to their entire face twice daily for 4 months. The researchers used 2D and 3D facial imaging to monitor changes in wrinkle visibility, skin roughness and wrinkle length in areas such as crow's feet, frown lines and forehead wrinkles.
The results showed that after 1, 3 and 4 months, participants who received the combined treatment with active peptides had significantly fewer wrinkles compared to those who received BTA and a placebo. This combined treatment prolonged the wrinkle-free period almost 8 weeks longer than BTA alone.
The synergy between BTA and Argireline® Amplified peptide meets the growing demand for effective and longer-lasting dermo-aesthetic solutions, allowing consumers to make fewer visits to the clinic and spend more time enjoying the benefits of smooth, youthful skin.